spacer
spacer

PDBsum entry 4ayd

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Immune system PDB id
4ayd

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
123 a.a.
117 a.a.
238 a.a.
Ligands
EDO ×4
Waters ×826
PDB id:
4ayd
Name: Immune system
Title: Structure of a complex between ccps 6 and 7 of human complement factor h and neisseria meningitidis fhbp variant 1 r106a mutant
Structure: Complement factor h. Chain: a, b, e. Fragment: ccps 6 and 7, residues 321-443. Synonym: h factor 1. Engineered: yes. Factor h binding protein. Chain: c, d, f. Fragment: residues 73-320. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Other_details: his402 polymorphism. Neisseria meningitidis. Organism_taxid: 122586. Strain: mc58.
Resolution:
2.40Å     R-factor:   0.204     R-free:   0.231
Authors: S.Johnson,L.Tan,S.Van Der Veen,J.Caesar,E.Goicoechea De Jorge, R.J.Everett,X.Bai,R.M.Exley,P.N.Ward,N.Ruivo,K.Trivedi,E.Cumber, R.Jones,L.Newham,D.Staunton,R.Borrow,M.Pickering,S.M.Lea,C.M.Tang
Key ref: S.Johnson et al. (2012). Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. Plos Pathog, 8, e1002981. PubMed id: 23133374
Date:
20-Jun-12     Release date:   07-Nov-12    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P08603  (CFAH_HUMAN) -  Complement factor H from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1231 a.a.
123 a.a.*
Protein chain
Pfam   ArchSchema ?
P08603  (CFAH_HUMAN) -  Complement factor H from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1231 a.a.
117 a.a.*
Protein chains
Pfam   ArchSchema ?
Q9JXV4  (Q9JXV4_NEIMB) -  Factor H binding protein from Neisseria meningitidis serogroup B (strain ATCC BAA-335 / MC58)
Seq:
Struc:
274 a.a.
238 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 3 residue positions (black crosses)

 

 
Plos Pathog 8:e1002981 (2012)
PubMed id: 23133374  
 
 
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules.
S.Johnson, L.Tan, S.van der Veen, J.Caesar, E.Goicoechea De Jorge, R.J.Harding, X.Bai, R.M.Exley, P.N.Ward, N.Ruivo, K.Trivedi, E.Cumber, R.Jones, L.Newham, D.Staunton, R.Ufret-Vincenty, R.Borrow, M.C.Pickering, S.M.Lea, C.M.Tang.
 
  ABSTRACT  
 
Neisseria meningitis remains a leading cause of sepsis and meningitis, and vaccines are required to prevent infections by this important human pathogen. Factor H binding protein (fHbp) is a key antigen that elicits protective immunity against the meningococcus and recruits the host complement regulator, fH. As the high affinity interaction between fHbp and fH could impair immune responses, we sought to identify non-functional fHbps that could act as effective immunogens. This was achieved by alanine substitution of fHbps from all three variant groups (V1, V2 and V3 fHbp) of the protein; while some residues affected fH binding in each variant group, the distribution of key amino underlying the interaction with fH differed between the V1, V2 and V3 proteins. The atomic structure of V3 fHbp in complex with fH and of the C-terminal barrel of V2 fHbp provide explanations to the differences in the precise nature of their interactions with fH, and the instability of the V2 protein. To develop transgenic models to assess the efficacy of non-functional fHbps, we determined the structural basis of the low level of interaction between fHbp and murine fH; in addition to changes in amino acids in the fHbp binding site, murine fH has a distinct conformation compared with the human protein that would sterically inhibit binding to fHbp. Non-functional V1 fHbps were further characterised by binding and structural studies, and shown in non-transgenic and transgenic mice (expressing chimeric fH that binds fHbp and precisely regulates complement system) to retain their immunogenicity. Our findings provide a catalogue of non-functional fHbps from all variant groups that can be included in new generation meningococcal vaccines, and establish proof-in-principle for clinical studies to compare their efficacy with wild-type fHbps.
 

 

spacer

spacer